Literature DB >> 28596251

Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis.

Martin Gorges1, Pauline Vercruysse1,2,3, Hans-Peter Müller1, Hans-Jürgen Huppertz4, Angela Rosenbohm1, Gabriele Nagel5, Patrick Weydt1, Åsa Petersén6, Albert C Ludolph3, Jan Kassubek1, Luc Dupuis2.   

Abstract

OBJECTIVE: Our objective was to study the hypothalamic volume in a cohort of patients with amyotrophic lateral sclerosis (ALS) including symptomatic and presymptomatic ALS mutation carriers.
METHODS: High-resolution three-dimensional T1-weighted MRI datasets from 251 patients with sporadic ALS, 19 symptomatic and 32 presymptomatic ALS mutation carriers and 112 healthy controls (HC) were retrospectivally registered for manual delineation of the hypothalamus. The volume of the hypothalamus, in total or subdivided, was normalised to the intracranial volume and adjusted to age. Correlation analyses were performed with clinical and metabolic outcomes. Pathologically defined ALS stages were determined in vivo by diffusion tensor imaging (DTI).
RESULTS: We observed a severe atrophy of the hypothalamus both in patients with sporadic ALS (-21.8%, p<0.0001) and symptomatic ALS mutation carriers (-13.4%, p<0.001). The atrophy in patients with sporadic ALS was observed in both the anterior (-27.6% p<0.0001) and the posterior parts of the hypothalamus (-17.7%, p<0.0001). Notably, this atrophy was also observed in presymptomatic ALS mutation carriers (-15.5%, p<0.001) and was unrelated to whole brain volume atrophy or disease stage as assessed using DTI or functional status. Hypothalamic volume was correlated with body mass index (BMI) in patients with sporadic ALS (p=0.0434, ρ=+0.1579), and this correlation was much stronger in patients with familial ALS (fALS) (p=0.0060, ρ=+0.6053). Anterior hypothalamic volume was correlated with age at onset, but not with survival after MRI.
CONCLUSIONS: Hypothalamus is atrophied in ALS, even in premorbid stages, and correlates with BMI, especially in fALS. Decreased anterior hypothalamic volume is associated with earlier onset of disease. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Year:  2017        PMID: 28596251     DOI: 10.1136/jnnp-2017-315795

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 2.  Physiological changes in neurodegeneration - mechanistic insights and clinical utility.

Authors:  Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-03-23       Impact factor: 42.937

Review 3.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

Review 4.  Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders.

Authors:  Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano
Journal:  Biomedicines       Date:  2022-05-10

5.  Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis.

Authors:  Maurine C Braun; Alexandra Castillo-Ruiz; Premananda Indic; Dae Young Jung; Jason K Kim; Robert H Brown; Steven J Swoap; William J Schwartz
Journal:  Exp Neurol       Date:  2018-07-18       Impact factor: 5.330

6.  Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia.

Authors:  Raphael Simon Peter; Angela Rosenbohm; Luc Dupuis; Torben Brehme; Jan Kassubek; Dietrich Rothenbacher; Gabriele Nagel; Albert Christian Ludolph
Journal:  Eur J Epidemiol       Date:  2017-10-03       Impact factor: 8.082

7.  Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study.

Authors:  Toshio Shimizu; Yuki Nakayama; Chiharu Matsuda; Michiko Haraguchi; Kota Bokuda; Kazuko Ishikawa-Takata; Akihiro Kawata; Eiji Isozaki
Journal:  J Neurol       Date:  2019-03-13       Impact factor: 4.849

Review 8.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

Review 9.  Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date.

Authors:  Ivana Štětkářová; Edvard Ehler
Journal:  Diagnostics (Basel)       Date:  2021-02-03

10.  Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients.

Authors:  David Bayer; Stefano Antonucci; Hans-Peter Müller; Rami Saad; Luc Dupuis; Volker Rasche; Tobias M Böckers; Albert C Ludolph; Jan Kassubek; Francesco Roselli
Journal:  Transl Neurodegener       Date:  2021-05-31       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.